Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brazil's President Eases Compulsory Licensing Law On Pandemic-Related Products

Executive Summary

Companies in Brazil will not have to provide know-how and other detailed information on patents that are subject to compulsory licenses during national or international emergencies, although other provisions of a law passed last year to ease the compulsory licensing process remain in place.

You may also be interested in...



EU Health Chief Under Pressure To Explain Delay In Legislative Overhaul

The latest delay to the European Commission’s proposals for revising the EU medicines legislation has caused consternation among members of the European Parliament who do not believe that the hold-up is due simply to a “busy agenda” at the commission.

NICE Confirms English Funding For Three COVID-19 Drugs, But Rejects Four Others

There is good news for medicines from Pfizer, GSK and Roche, but MSD, Gilead and AstraZeneca have all appealed against NICE’s decision not to recommend their products for treating COVID-19.

EU Sets New Date For Publication Of Delayed Pharma Revision Proposals

Lengthy legislative procedures are expected after the commission publishes its “pharma package” and the “patent package,” which are now due towards the end of April.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel